MTOR and hereditary clear cell renal cell carcinoma: This figure is similar to those administered to humans in clinical settings, such as the use of rapamycin for the treatment of glioblastoma (up to 10 mg daily for multiple days), the use of temsirolimus for the treatment of renal cell carcinoma (25 mg once weekly), or the use of everolimus for the treatment of tuberous sclerosis (TS), a genetic disorder resulting in hyperactivation of mTOR (10 mg daily, continuously) [23, 58–60].